More Articles

Market Access

Face Value

Danielle Barron, (Feb 21, 2017)

With oncology drug prices under intense and growing scrutiny, how are companies proving the value of their medicines?
Market Access

Strength in Numbers

Danielle Barron, (Feb 20, 2017)

R&D innovation is being accelerated through the nurturing of a ground breaking public-private relationship
Market Access

Access All Areas

Deirdre Coleman, (Feb 15, 2017)

Numerous barriers impede the full realization of benefit from Real World Evidence

One Giant Leap for Medical Affairs

Deirdre Coleman, (Feb 14, 2017)

Pharma’s engine of growth lies firmly within Medical Affairs and its ability to partner effectively with other functions.
Market Access

The Price of Everything and the Value of Nothing

Hugh Gosling, (Feb 9, 2017)

What is value and how do we prove it? Economist Dr Jason Shafrin talks prices, politics and the problem of monopolies.

The Real Emotional Sell

Pamela Walker, (Feb 7, 2017)

What are the three key elements that any rep can leverage for a more compelling sell?

Customer Experience: Through Thick and Thin

Hugh Gosling, (Jan 26, 2017)

Enhancing customer experience to improve loyalty could be pharma’s next big step forward

The Art of Mastering Adaptive Engagement

Deirdre Coleman, (Jan 25, 2017)

The age of consumer empowerment is in full force and the industry must respond and adapt to customer engagement.

Successful Collaboration Lies Within

Hugh Gosling, (Jan 24, 2017)

To shape the external environment we must prepare ourselves internally, says Janssen's Rebecca Hutchinson
Market Access

Real-World Revolution Part 2

Deirdre Coleman, (Jan 23, 2017)

Changing mindsets in clinical research